Loading...

BriaCell Therapeutics Corp.

BCT.TO•TSX
Healthcare
Biotechnology
CA$10.41
CA$0.91(9.58%)

BriaCell Therapeutics Corp. (BCT.TO) Stock Overview

Explore BriaCell Therapeutics Corp.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.9/100

Key Financials

Market Cap182.7M
P/E Ratio-1.43
EPS (TTM)$-106.70
ROE-4.40%
Fundamental Analysis

AI Price Forecasts

1 Week$4.62
1 Month$-4.24
3 Months$10.45
1 Year Target$8.63

BCT.TO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of BriaCell Therapeutics Corp. (BCT.TO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 93.56, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $8.63.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.43 and a market capitalization of 182.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-2.23%
5-Day Change
15.12%
1-Month Change
15.59%
3-Month Change
-35.48%
6-Month Change
-72.21%
Year-to-Date (YTD) Change
-53.58%
1-Year Change
-89.71%
3-Year Change
-97.41%
5-Year Change
-95.87%
All-Time (Max) Change
-99.87%

Contact Information

https://www.briacell.com
604-921-1810
Bellevue Centre, West Vancouver, BC, V7T 2X1

Company Facts

16 Employees
IPO DateAug 13, 2012
CountryCA
Actively Trading

Frequently Asked Questions

;